Gene Rearrangement and Expression of PRKACA and PRKACB Govern Morphobiology of Pancreatobiliary Oncocytic Neoplasms

Mod Pathol. 2024 Jan;37(1):100358. doi: 10.1016/j.modpat.2023.100358. Epub 2023 Oct 21.

Abstract

Intraductal oncocytic papillary neoplasms (IOPNs) are distinct from intraductal papillary mucinous neoplasms based on characteristic morphologic and genetic features represented by fusion genes involving PRKACA or PRKACB (PRKACA/B). However, pancreatic and biliary tumors with partial oncocytic features are often encountered clinically, and their molecular features are yet to be clarified. This study included 80 intraductal papillary neoplasms: 32 tumors with mature IOPN morphology (typical), 28 with partial or subclonal oncocytic features (atypical), and 20 without oncocytic features (control). We analyzed PRKACA/B fusion genes, including ATP1B1::PRKACA, DNAJB1::PRKACA, and ATP1B1::PRKACB, by reverse-transcription PCR; mRNA expression of fusion genes and nonrearranged PRKACA/B genes by quantitative reverse-transcription PCR; mutations in KRAS, BRAF, and GNAS by targeted sequencing or droplet digital PCR; and the expression of cyclic adenosine monophosphate (cAMP)-dependent protein kinase catalytic subunits α (PRKACA) and β (PRKACB), phosphorylated cAMP response element-binding protein, and aberrations of p16, p53, SMAD4, STK11, and β-catenin by immunohistochemistry. PRKACA/B fusion genes were detected in 100% (32/32) of typical, 46% (13/28) of atypical, and 0% (0/20) of control (P < .05). Expression of PRKACA, PRKACB, and phosphorylated cAMP response element-binding protein was upregulated in neoplasms with PRKACA/B fusion genes (P < .05). mRNA expression of the PRKACA/B fusion genes and protein expression of PRKACA or PRKACB tended to be higher in typical than in atypical cases (mRNA, P = .002; protein expression, P = .054). In some atypical neoplasms with mixed subtypes, PRKACA/B fusion genes were superimposed exclusively on oncocytic components. Typical IOPNs harbored fewer KRAS and GNAS mutations than control samples and fewer alterations in p53 and STK11 than atypical samples (P < .05). In conclusion, PRKACA/B fusion genes not only are the characteristic drivers of IOPNs but also play a crucial role in the development of subclonal oncocytic neoplasms. Moreover, oncocytic morphology is strongly associated with upregulation of PRKACA/B, which may provide clues for potential therapeutic options.

Keywords: IOPN; IPMN; IPNB; PRKACA; PRKACB.

MeSH terms

  • Adenocarcinoma, Mucinous* / pathology
  • Carcinoma, Pancreatic Ductal* / pathology
  • Catalytic Domain
  • Chromosome Aberrations
  • Cyclic AMP Response Element-Binding Protein / genetics
  • Cyclic AMP-Dependent Protein Kinase Catalytic Subunits / genetics
  • Gene Rearrangement
  • HSP40 Heat-Shock Proteins / genetics
  • Humans
  • Pancreatic Neoplasms* / pathology
  • Protein Kinases / genetics
  • Proto-Oncogene Proteins p21(ras) / genetics
  • RNA, Messenger
  • Tumor Suppressor Protein p53 / genetics

Substances

  • Tumor Suppressor Protein p53
  • Protein Kinases
  • Cyclic AMP Response Element-Binding Protein
  • Proto-Oncogene Proteins p21(ras)
  • RNA, Messenger
  • DNAJB1 protein, human
  • HSP40 Heat-Shock Proteins
  • PRKACA protein, human
  • Cyclic AMP-Dependent Protein Kinase Catalytic Subunits
  • PRKACB protein, human